{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T08:50:42Z","timestamp":1768726242937,"version":"3.49.0"},"reference-count":22,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T00:00:00Z","timestamp":1361750400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0056327","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T17:14:38Z","timestamp":1361812478000},"page":"e56327","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["BCG-Mediated Bladder Cancer Immunotherapy: Identifying Determinants of Treatment Response Using a Calibrated Mathematical Model"],"prefix":"10.1371","volume":"8","author":[{"given":"Cyrill A.","family":"Rentsch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Biot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00ebl R.","family":"Gsponer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew L.","family":"Albert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romulus","family":"Breban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2013,2,25]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S0022-5347(17)59210-1","article-title":"Bacillus Calmette-Guerin in the treatment of adenocarcinoma of the kidney","volume":"115","author":"A Morales","year":"1976","journal-title":"J Urol"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/onci.1.1.17884","article-title":"Mathematical model of tumor immunotherapy for bladder carcinoma identifies the limitations of the innate immune response","volume":"1","author":"R Breban","year":"2012","journal-title":"OncoImmunology"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI34388","article-title":"Two-photon imaging of intratumoral CD8+ T cell cytotoxic activity during adoptive T cell therapy in mice","volume":"118","author":"B Breart","year":"2008","journal-title":"J Clin Invest"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"044109","DOI":"10.1063\/1.2159468","article-title":"Efficient step size selection for the tau-leaping simulation method","volume":"124","author":"Y Cao","year":"2006","journal-title":"J Chem Phys"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.juro.2008.11.124","article-title":"Molecular analyte profiling of the early events and tissue conditioning following intravesical bacillus calmette-guerin therapy in patients with superficial bladder cancer","volume":"181","author":"A Bisiaux","year":"2009","journal-title":"J Urol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1146\/annurev.immunol.021908.132703","article-title":"Cell-mediated immune responses in tuberculosis","volume":"27","author":"AM Cooper","year":"2009","journal-title":"Annu Rev Immunol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"137ra172","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-Specific T Cells Improve Intravesical Immunotherapy for Bladder Cancer","volume":"4","author":"C Biot","year":"2012","journal-title":"Sci Transl Med"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study","volume":"163","author":"DL Lamm","year":"2000","journal-title":"J Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial","volume":"44","author":"AP van der Meijden","year":"2003","journal-title":"Eur Urol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0022-5347(17)37707-8","article-title":"A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?","volume":"146","author":"F Pagano","year":"1991","journal-title":"J Urol"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Losa A, Hurle R, Lembo A (2000) Low dose bacillus Calmette-Guerin for carcinoma in situ of the bladder: long-term results. J Urol 163: 68-71; discussion 71\u201362.","DOI":"10.1097\/00005392-200001000-00017"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1464-410X.1995.tb07308.x","article-title":"Low-dose bacille Calmette-Guerin (BCG) therapy in superficial high-risk bladder cancer: a phase II study with the BCG strain Connaught Canada","volume":"75","author":"D Mack","year":"1995","journal-title":"Br J Urol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"JA Martinez-Pineiro","year":"2002","journal-title":"BJU Int"},{"key":"ref14","first-page":"1398","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C. Eur Urol","volume":"52","author":"A Ojea","year":"2007"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.urology.2007.07.017","article-title":"The safety and efficacy of different doses of bacillus Calmette Guerin in superficial bladder transitional cell carcinoma","volume":"70","author":"MS Agrawal","year":"2007","journal-title":"Urology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/j.1464-410X.2005.05817.x","article-title":"Intravesical bacillus Calmette-Guerin therapy: experience with a reduced dwell-time in patients with pronounced side-effects","volume":"96","author":"P Andius","year":"2005","journal-title":"BJU Int"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.eururo.2005.05.004","article-title":"BCG dose reduction by decreasing the instillation frequency: effects on local Th1\/Th2 cytokine responses in a mouse model","volume":"48","author":"EC de Boer","year":"2005","journal-title":"Eur Urol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000052380","article-title":"Modified induction course: a solution to side-effects?","volume":"37","author":"P Bassi","year":"2000","journal-title":"Eur Urol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1007\/s11538-007-9195-z","article-title":"Mathematical model of BCG immunotherapy in superficial bladder cancer","volume":"69","author":"S Bunimovich-Mendrazitsky","year":"2007","journal-title":"Bull Math Biol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.3934\/mbe.2011.8.529","article-title":"Use of quasi-normal form to examine stability of tumor-free equilibrium in a mathematical model of BCG treatment of bladder cancer","volume":"8","author":"S Bunimovich-Mendrazitsky","year":"2011","journal-title":"Math Biosci Eng"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jtbi.2011.02.008","article-title":"A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancer","volume":"277","author":"S Bunimovich-Mendrazitsky","year":"2011","journal-title":"J Theor Biol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1007\/s11538-008-9344-z","article-title":"Mathematical model of pulsed immunotherapy for superficial bladder cancer","volume":"70","author":"S Bunimovich-Mendrazitsky","year":"2008","journal-title":"Bull Math Biol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0056327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T23:26:20Z","timestamp":1562714780000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0056327"}},"subtitle":[],"editor":[{"given":"David J.","family":"Klinke","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2013,2,25]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2013,2,25]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0056327","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,25]]}}}